Many women with inflammatory bowel disease (IBD) notice their gut symptoms shift with their menstrual cycle, worsen during pregnancy, or change around menopause. These patterns are not coincidental. Hormones, particularly oestrogen and progesterone, interact directly with the immune system and gut lining in ways that influence inflammation, motility, and symptom severity.
What are sex hormones and how do they affect the gut?
Sex hormones are chemical messengers produced primarily by the ovaries. Oestrogen and progesterone fluctuate throughout the menstrual cycle, pregnancy, and menopause. Both have receptors in the gut lining, immune cells, and the bacteria that make up the microbiome, meaning the gut is actively influenced by hormonal changes.
Oestrogen rises in the first half of the menstrual cycle and falls sharply before menstruation. Progesterone peaks after ovulation and drops if pregnancy does not occur. These fluctuations can alter gut permeability, bacterial balance, immune cell activity, and digestive transit speed.
Why this matters for women with IBD
Women with Crohn’s disease or ulcerative colitis often report symptoms worsening at certain cycle points, most commonly in the days before or during menstruation. Research confirms that hormonal fluctuations can influence disease activity, though effects vary between individuals.
Oestrogen is generally anti-inflammatory at moderate levels, but high or rapidly changing levels can trigger immune activation. Progesterone promotes immune tolerance but can slow gut motility, causing constipation or bloating. During menstruation, when both hormones drop, some women experience increased abdominal pain, diarrhoea, or urgency.
Understanding these patterns helps women and healthcare teams distinguish between hormonal symptom flares and true inflammatory activity, which is important for treatment decisions.
The gut-hormone connection: key mechanisms
Oestrogen and immune modulation
Oestrogen affects T cell and B cell activity, part of the adaptive immune system. At moderate levels, it can suppress pro-inflammatory cytokines that drive IBD inflammation. However, it can also enhance antibody production and shift immune cell balance in ways that may increase autoimmune activity. This dual effect may explain why some women feel better during certain cycle phases and worse during others.
Progesterone and gut motility
Progesterone slows digestive tract movement by relaxing smooth muscle. This causes constipation and bloating in the second half of the menstrual cycle and during pregnancy. In women with IBD, this slowing can worsen obstruction symptoms or cause fullness and discomfort, even without active inflammation.
Hormones and the gut microbiome
The gut microbiome is influenced by oestrogen. Some bacterial species can metabolise oestrogen and produce compounds affecting hormone levels. This bidirectional relationship means hormonal changes alter microbiome composition, whilst microbiome changes influence how hormones are processed. Women with IBD may already have altered microbiomes, and hormonal fluctuations add another layer of instability.
The role of the oestrobolome
A subset of gut bacteria called the oestrobolome produces enzymes that break down oestrogen. When disrupted, oestrogen can be reabsorbed rather than excreted, leading to higher circulating levels and potential oestrogen dominance, which may worsen inflammation and gut symptoms. Maintaining a diverse, balanced microbiome may support healthier oestrogen metabolism.
Menstruation and prostaglandins
During menstruation, the uterus releases prostaglandins, lipid compounds that cause uterine contractions. Prostaglandins also affect the intestines, increasing motility and potentially triggering diarrhoea, cramping, and urgency. Women with IBD may be more sensitive to these effects, and the combination of prostaglandin release and existing gut inflammation can lead to particularly difficult days.
Pregnancy, menopause, and long-term hormonal shifts
Pregnancy brings sustained high oestrogen and progesterone levels, with varying IBD effects. Some women experience remission, possibly due to high progesterone’s immune-modulating effects. Others experience worsening symptoms, particularly in the first trimester or postpartum when hormone levels drop sharply.
Menopause brings permanent oestrogen and progesterone decline. Some women find their IBD symptoms stabilise afterwards, whilst others notice increased joint pain, gut motility changes, or worsening fatigue. Hormone replacement therapy may help manage menopausal symptoms, but its IBD effects are not fully understood and should be discussed with a gastroenterologist.
Practical takeaways
- Track your symptoms alongside your menstrual cycle to identify patterns. This helps you and your healthcare team distinguish between hormonal flares and true disease activity.
- Discuss hormonal influences with your gastroenterologist, particularly if you notice consistent symptom changes around menstruation, ovulation, or during pregnancy.
- Support your microbiome through a varied diet rich in fibre from tolerated plant foods, fermented foods if appropriate, and omega-3 fatty acids, which may help modulate inflammation and support microbial diversity.
- Consider NSAID avoidance during menstruation, as drugs like ibuprofen can worsen gut inflammation in people with IBD.
- If entering menopause or considering hormone replacement therapy, involve your IBD team in the decision to ensure hormonal treatments are compatible with your gut health.
Conclusion
The relationship between hormones and the gut is complex, bidirectional, and highly individual. For women with IBD, hormonal fluctuations can influence inflammation, symptom severity, and quality of life. Recognising these patterns does not replace medical treatment, but offers clearer understanding of what is happening in your body and why certain times or life stages may feel more difficult. Working with your healthcare team to track and respond to these changes can support more stable, long-term management.
References
- Houghton LA, Heitkemper M, Crowell MD, et al. Age, gender, and women’s health and the patient. Gastroenterology. 2016;150(6):1332-1343. doi:10.1053/j.gastro.2016.02.017
- Khalili H, Granath F, Smedby KE, et al. Association between long-term oral contraceptive use and risk of Crohn’s disease complications in a nationwide study. Gastroenterology. 2016;150(7):1561-1567. doi:10.1053/j.gastro.2016.02.041
- Cornish J, Tan E, Simillis C, et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum. 2007;50(8):1128-1138. doi:10.1007/s10350-007-0240-7
- Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: physiological and clinical implications. Maturitas. 2017;103:45-53. doi:10.1016/j.maturitas.2017.06.025
- Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril. 2018;109(6):952-963. doi:10.1016/j.fertnstert.2018.05.006
- Kane SV, Reddy D. Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103(5):1193-1196. doi:10.1111/j.1572-0241.2007.01700.x
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.